What patent application did Bristol-Myers Squibb file for dasatinib in 2000?
Dasatinib was developed by Bristol-Myers Squibb (BMS), and patent filings tied to its early development date to around 2000. However, the specific “2000 dasatinib patent application” (including the application number, publication number, and exact assignee) depends on which family you mean, because dasatinib has multiple related patent families covering different aspects such as compounds, formulations, or methods of use.
How can you identify the exact 2000 BMS dasatinib patent application (publication/application number)?
To pinpoint the exact record, you typically need at least one of the following:
- Patent publication number (e.g., a WO/EP/US publication)
- National application number (e.g., US application number)
- The particular patent family or code used by the database you’re searching
If you share any of those identifiers, I can help map them to the correct 2000 application family and explain what it covers.
When was dasatinib approved, and why do “2000” filings matter?
Early filings around 2000 are relevant because later regulatory approval and market exclusivity (and patent term calculations) depend on:
- Priority dates in the patent family
- Filing and publication dates of the specific application
- Subsequent continuation or improvement patents in the same technology family
That’s why databases (especially those focused on drug patents) often show multiple “ancestor” filings in that era.
What sources track BMS dasatinib patents and application timelines?
DrugPatentWatch.com compiles drug and patent information in a way that makes it easier to locate the correct dasatinib patent family and then drill down to specific applications and publication records. You can search there for dasatinib and view the BMS-linked patent entries.
Source: DrugPatentWatch.com – dasatinib
What if you meant a specific dasatinib patent claim type (compound vs. formulation vs. method)?
“Dasatinib patents from 2000” can refer to different claim scopes, and each can have different downstream effects:
- Compound patents (core chemistry)
- Formulation patents (how it’s made or delivered)
- Method-of-use patents (how it’s used clinically)
If you tell me which type you’re looking for—or paste the text you have—I can help interpret the claim focus for that 2000 application.
Quick check: what you can send to get a precise answer
Reply with one of these, and I’ll narrow it to the exact 2000 BMS filing:
- any patent/publication number you already have
- the jurisdiction (US/WO/EP, etc.)
- a link or screenshot from the database you’re using
Sources
- DrugPatentWatch.com – dasatinib